Veli Matti Wasenius

Summary

Affiliation: University of Helsinki
Country: Finland

Publications

  1. ncbi request reprint MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma
    Veli Matti Wasenius
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Am J Surg Pathol 29:544-9. 2005
  2. ncbi request reprint Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study
    Veli Matti Wasenius
    Department of Oncology, Helsinki University Central Hospital, FIN 00029 Helsinki, Finland
    Clin Cancer Res 9:68-75. 2003
  3. ncbi request reprint Alterations in the suppressor gene PPP2R1B in parathyroid hyperplasias and adenomas
    Samuli Hemmer
    Department of Oncology, Haartmaninkatu 4, P O Box 180, FIN 00029 HUS, Helsinki, Finland
    Cancer Genet Cytogenet 134:13-7. 2002
  4. pmc Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors
    Rainer Lehtonen
    Department of Medical Genetics, Haartman Institute, University of Helsinki, Finland
    Am J Pathol 164:17-22. 2004
  5. ncbi request reprint High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer
    Petri Bono
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Clin Cancer Res 10:7144-9. 2004

Collaborators

  • H Joensuu
  • David G Jackson
  • Petri Bono
  • Knuutila Sakari
  • Leena Maija Aaltonen
  • Charis Eng
  • Rainer Lehtonen
  • Samuli Hemmer
  • Auli Karhu
  • Virpi Launonen
  • Paivi Peltomaki
  • Nina N Nupponen
  • Jari Sj√∂berg
  • Johanna Arola
  • Maija Kiuru
  • Sakari Vanharanta
  • Kristiina Aittomaki
  • Ralf Butzow
  • Pasi Koivisto
  • Reijo Salovaara
  • Kirsti Husgafvel-Pursiainen
  • Jorma Isola
  • Heikki Jarvinen
  • Jukka Pekka Mecklin
  • Ying Zhu
  • Kaarle Franssila
  • Caj Haglund
  • Sakari Knuutila

Detail Information

Publications5

  1. ncbi request reprint MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma
    Veli Matti Wasenius
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Am J Surg Pathol 29:544-9. 2005
    ..We conclude that MET(T1010I) sequence alteration is relatively frequent in differentiated thyroid carcinoma. The clinical and the molecular pathologic significance of this MET sequence alteration is not known...
  2. ncbi request reprint Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study
    Veli Matti Wasenius
    Department of Oncology, Helsinki University Central Hospital, FIN 00029 Helsinki, Finland
    Clin Cancer Res 9:68-75. 2003
    ....
  3. ncbi request reprint Alterations in the suppressor gene PPP2R1B in parathyroid hyperplasias and adenomas
    Samuli Hemmer
    Department of Oncology, Haartmaninkatu 4, P O Box 180, FIN 00029 HUS, Helsinki, Finland
    Cancer Genet Cytogenet 134:13-7. 2002
    ..We conclude mutations of PPP2R1B are not frequent in parathyroid lesions, and that other genes located at 11q23 may be more closely associated with pathogenesis of parathyroid hyperplasia and adenoma...
  4. pmc Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors
    Rainer Lehtonen
    Department of Medical Genetics, Haartman Institute, University of Helsinki, Finland
    Am J Pathol 164:17-22. 2004
    ..Our data also indicate that somatic FH mutations appear to be limited to tumor types observed in hereditary leiomyomatosis and renal cell cancer...
  5. ncbi request reprint High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer
    Petri Bono
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Clin Cancer Res 10:7144-9. 2004
    ..LYVE-1, a lymphatic endothelium-specific hyaluronan receptor, is a novel lymphatic vessel marker that is expressed on lymph vessel endothelial cells of both normal and neoplastic tissues...